scholarly journals Comparison of surgical outcomes of sponge application versus subconjunctival injection of Mitomycin-C during combined phacoemulsification and trabeculectomy surgery in Asian eyes

2021 ◽  
Vol 33 (3) ◽  
pp. 253
Author(s):  
BryanChin Hou Ang ◽  
Wenqi Chiew ◽  
Xiner Guo ◽  
AngelaPek Hoon Lim ◽  
LeonardWei Leon Yip
2012 ◽  
Vol 40 (4) ◽  
pp. e143-e148 ◽  
Author(s):  
Kenneth CY Chan ◽  
Ghee S Ang ◽  
Wayne Birchall ◽  
Tracey Wong ◽  
Laura Wakely ◽  
...  

2020 ◽  
Vol 220 ◽  
pp. 45-52
Author(s):  
Jiun L. Do ◽  
Benjamin Y. Xu ◽  
Brandon Wong ◽  
Andrew Camp ◽  
Philip Ngai ◽  
...  

1998 ◽  
Vol 212 (5) ◽  
pp. 306-309 ◽  
Author(s):  
I. Pinilla ◽  
J.M. Larrosa ◽  
V. Polo ◽  
F.M. Honrubia

2019 ◽  
pp. 154-169
Author(s):  
Fiscella R ◽  
Leiter CW ◽  
Massoomi F ◽  
Noecker R ◽  
Sheybani A

Background: Antifibrotics and antimetabolites, including 5-fluorouracil (5-FU) and mitomycin C (MMC), have been used for decades to improve ophthalmic surgical outcomes, most notably with glaucoma filtering procedures. Adjuvant MMC and 5-FU also enhance the efficacy of minimally invasive subconjunctival drainage implants now being used. The authors feel that a review of the usage and safety of these agents is merited, especially in light of updated and new USP guidelines for compounded and hazardous drugs.Main Body: The mode of perioperative administration of MMC during glaucoma surgery is evolving with a shift from the traditional sponge application to subconjunctival injection, allowing for a more precise dosing and controlled administration of this medication. Several studies demonstrate effective use of MMC and 5-FU, at a variety of different doses. Most of these studies use compounded MMC and 5-FU. Glaucoma surgeons must be careful in how they source MMC, however, as the U.S. Food & Drug Administration (FDA) expects physicians to use FDA-approved drug products when clinically appropriate. When a physician determines a compounded version of MMC is clinically necessary for an individual patient, the FDA closely regulates how and when drug products can be compounded and by what type of facilities. There will also be additional increased scrutiny on storage and disposal of MMC and 5-FU as new regulations are introduced.Conclusion: This review of MMC and 5-FU and their role in glaucoma surgery will address questions regarding drug safety, procurement, use, and disposal.


1997 ◽  
Vol 7 (4) ◽  
pp. 340-344 ◽  
Author(s):  
L.E. Pablo ◽  
T. Ramirez ◽  
M. Pueyo ◽  
J.M. Larrosa ◽  
V. Polo ◽  
...  

Aim Single or multiple subconjunctival injections of mitomycin-C (MMC) may offer one way of establishing the total dosage of MMC more accurately. The method also allows re-applications later postoperatively. In this experimental, randomized prospective study we compared the effects of a single intraoperative application of MMC at the filtering site and a single postoperative subconjunctival injection of the drug. Methods The left eyes of 32 pigmented rabbits were divided into two groups. In the first group we applied MMC intraoperatively (10) with a 4×1 mm surgical sponge soaked in a MMC solution (0.5 mg/ml). In the second group we injected 0.4 ml of the same solution subconjunctivally (SC) immediately after (conjunctival) suture. Post-operative evaluation was carried out every day during the first week, then every three days until day 58. Survival analyses were done for intraocular pressure (IOP) and bleb failure. Log-rank tests were used to compare survival differences between the groups. Results The IO group showed longer survival parameters than the SC group (p<0.05), both in the control of IOP and as regards blebs. The histological persistence of fistulas was similar. The IO group, however, had a higher incidence of undesirable side effects. Conclusions Our findings suggest IO application of MMC is more effective in reducing fibroblast ingrowth. However, subconjunctival application offers certain advantages such as the possibility of repeating the treatment postoperatively and, therefore, using a smaller initial dose.


1995 ◽  
Vol 11 (3) ◽  
pp. 233-241 ◽  
Author(s):  
POR T. HUNG ◽  
LUKE L.K. LIN ◽  
JUI W. HSIEH ◽  
TSING H. WANG

Sign in / Sign up

Export Citation Format

Share Document